LOV 3.75 Spark Networks Plc $LOV Hit a 52 week low of 3.75

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 10:44 PM

LOV 3.75 Spark Networks Plc $LOV Hit a 52 week low of 3.75 Closing the day 11/10/14 at 3.75 -0.07 -1.83% With a day low of 3.75 and a total volume of 21,115.

LOV Recent Posts: http://investorshangout.com/Spark-Networks-Plc-LOV-56951/

LOV Spark Networks Plc Recent Headline News

Spark Networks (LOV) Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 12:37AM CST

LOV: 3.75 (-0.07)

Spark Networks beats by $0.01, revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:18PM CST

LOV: 3.75 (-0.07)

Spark Networks(R) Reports Third Quarter Financial Results
Marketwired - Thu Nov 06, 3:07PM CST
Spark Networks, Inc. (NYSE MKT: LOV)
LOV: 3.75 (-0.07)

Brightcove, Inc. (BCOV) Surges: Stock Rises 18.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:11AM CST
Brightcove, Inc. (BCOV) was a big mover last session, as the company saw its shares rise nearly 19% on the day.
DHX: 10.94 (+0.41), BCOV: 6.88 (+0.20), GAME: 6.47 (+0.02), LOV: 3.75 (-0.07)

Shutterfly Q3 Loss Narrower than Expected, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:10PM CDT
Shutterfly Inc. (SFLY) posted third-quarter results with a loss that was narrower than the Zacks Consensus Estimate while revenues missing the consensus mark.
BCOV: 6.88 (+0.20), SFLY: 41.49 (-0.19), GAME: 6.47 (+0.02), LOV: 3.75 (-0.07)

Changyou.com (CYOU) Soars: Stock Adds 13.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:57AM CDT
Changyou.com Limited (CYOU) was a big mover last session, as the company saw its shares rise nearly 14% on the day.
DL: 14.08 (unch), SFLY: 41.49 (-0.19), CYOU: 23.40 (+0.99), LOV: 3.75 (-0.07)

Spark Networks(R) Announces Investor Conference Call to Discuss Third Quarter 2014 Financial Results
Marketwired - Thu Oct 23, 7:25PM CDT
Spark Networks, Inc. (NYSE MKT: LOV), a leader in creating niche-focused brands that build and strengthen the communities they serve, will host an investor conference call to discuss its results for the third quarter 2014. The call is scheduled to take place on Thursday, November 6, 2014 at 1:30 p.m. Pacific Time.
LOV: 3.75 (-0.07)

Weakness Seen in Shutterstock (SSTK): Stock Falls 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 7:31AM CDT
Shutterstock (SSTK) fell over 5% in the last trading session amid huge volumes, breaking its recent volatile trend as it is currently trading below the volatile price range of last one month.
YY: 82.43 (+2.93), XOXO: 14.38 (-0.12), SSTK: 80.67 (+1.49), LOV: 3.75 (-0.07)

Angie's List (ANGI) in Focus: Stock Rises 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 7:30AM CDT
Angie's List, Inc. (ANGI) was a big mover last session, as the company saw its shares rise over 7% on the day.
YY: 82.43 (+2.93), ANGI: 6.52 (-0.09), LOV: 3.75 (-0.07), ENT: 13.38 (+0.65)

Taomee Holdings Ltd. (TAOM) Rises: Stock Jumps 5.30% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 8:32AM CDT
Taomee Holdings Ltd. (TAOM) was a big mover last session, as the company saw its shares rise more than 5% on the day.
TAOM: 4.07 (+0.07), YY: 82.43 (+2.93), LOV: 3.75 (-0.07), ENT: 13.38 (+0.65)

ROSG, BCOM, ENTR, HEES, LOV, ARI Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Wed Sep 24, 3:33AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Rosetta Genomics Ltd (NASDAQ:ROSG), B Communications Ltd (NASDAQ:BCOM), Entropic Communications Inc (NASDAQ:ENTR), H&E Equipment Services Inc (NASDAQ:HEES), Spark Networks Inc (NYSE:LOV), Apollo Commercial Real Estate Finance Inc (NYSE:ARI) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ROSG: 2.68 (-0.05), BCOM: 20.94 (+1.59), ARI: 16.58 (+0.13), HEES: 38.57 (+0.20), LOV: 3.75 (-0.07), ENTR: 2.71 (+0.21)

Spark Networks(R) Completes Corporate Restructuring to Better Position the Company for Profitable Growth
Marketwire - Tue Sep 16, 8:15AM CDT
On September 15, 2014, Spark Networks, Inc. (NYSE MKT: LOV) (the "Company"

implemented a workforce and expense reduction initiative to improve operating efficiency and better position the Company for profitable growth. Annualized savings are estimated to be between $4.5mm and $5.0mm. The workforce and expense reduction is substantially complete.
LOV: 3.75 (-0.07)

Why You Shouldn't Bet Against Spark Networks (LOV) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 7:40AM CDT
Spark Networks is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.
LOV: 3.75 (-0.07)

Investors' Radars Failed to Catch Spark Networks (LOV), Has Yours? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 7:48AM CDT
Spark Network’s solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for this stock and that now might be an interesting buying opportunity.
LOV: 3.75 (-0.07)

Spark Networks(R) Announces Departure of Greg Liberman as President and CEO
Marketwire - Mon Aug 11, 4:05PM CDT
Spark Networks, Inc. (NYSE MKT: LOV), a leader in creating niche-focused brands that build and strengthen the communities they serve, today announced the departure of President & Chief Executive Officer, Greg Liberman, effective today. The Company also announced that it will immediately begin the process to identify a successor and Michael McConnell, the Company's Chairman of the Board, will serve as Executive Chairman during the transition period.
LOV: 3.75 (-0.07)

Spark Networks(R) Reports Second Quarter Financial Results
Marketwire - Mon Aug 11, 3:01PM CDT
Spark Networks, Inc. (NYSE MKT: LOV)
LOV: 3.75 (-0.07)

Spark Networks Shares Up 9.2% Since SmarTrend's Buy Recommendation (LOV)
Comtex SmarTrend(R) - Fri Aug 01, 11:20AM CDT
SmarTrend identified an Uptrend for Spark Networks (AMEX:LOV) on June 23rd, 2014 at $5.35. In approximately 1 month, Spark Networks has returned 9.16% as of today's recent price of $5.84.
LOV: 3.75 (-0.07)

Spark Networks(R) Announces Investor Conference Call to Discuss Second Quarter 2014 Financial Results
Marketwire - Mon Jul 28, 3:05PM CDT
Spark Networks, Inc. (NYSE MKT: LOV), a leader in creating niche-focused brands that build and strengthen the communities they serve, will host an investor conference call to discuss its results for the second quarter 2014. The call is scheduled to take place on Monday, August 11, 2014 at 1:30 p.m. Pacific Time.
LOV: 3.75 (-0.07)

13.6% Return Seen to Date on SmarTrend Spark Networks Call (LOV)
Comtex SmarTrend(R) - Fri Jul 25, 9:58AM CDT
SmarTrend identified an Uptrend for Spark Networks (AMEX:LOV) on June 23rd, 2014 at $5.35. In approximately 1 month, Spark Networks has returned 13.64% as of today's recent price of $6.08.
LOV: 3.75 (-0.07)

Spark Networks(R) Names Michael McConnell Chairman and Appoints Ian Jacobs to Board
Marketwire - Mon Jul 07, 4:23PM CDT
Spark Networks, Inc. (NYSE MKT: LOV), a leader in creating niche-focused brands that build and strengthen the communities they serve, announced today the appointment of Michael J. McConnell as the Chairman of the Board of Directors and the appointment of Ian V. Jacobs to its Board of Directors.
LOV: 3.75 (-0.07)

Spark Networks Plc (LOV) Stock Research Links

LOV Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...